Evaluation of a Cincalcet Suppression Test
Evaluation of a Cincalcet Suppression Test
The aim of the study is to compare the results of a parathyroid hormone (PTH)suppression test
 using a single oral tablet of cinacalcet in two groups of subjects: 1- a group of healthy
 adults in whom the results of the test with cinacalcet will be compared with those of the
 standardized PTH suppression test with intravenous calcium loading; 2- a group of patients
 with proven primary hyperparathyroidism in whom the results of the test with cinacalcet will
 be compared with those obtained during the same test, in healthy controls.
Inclusion Criteria:

 -  Control group: healthy adult (>18 years), having signed informed consent, taking no
 treatment, with effective contraception in unmenopausal women, with normal clinical
 examination, with normal plasma PTH, calcium, phosphorus, 25 OH vitamin D levels, with
 normal renal function, with normal 24 hour calciuria.

 -  Primary hyperparathyroidism group: adult patients (>18 years), having signed informed
 consent, with effective contraception in unmenopausal women, taking no treatment known
 to modify calcium-phosphorus status, with normal BMI, in which the diagnosis of
 primary hyperparathyroidism was confirmed on plasma PTH, calcium, phosphorus, 25 OH
 vitamin D levels, with normal renal function, with 24 hour calciuria higher than
 normal.

 Exclusion Criteria:

 -  Control group: significant medical or surgical history, creatinine clearance <60
 ml/min, liver insufficiency, arterial hypertension, psychiatric disorder able to
 modify the compliance to the study, tobacco intoxication, taking a treatment known to
 modify calcium-phosphorus status, severe known allergy, pregnant women, unmenopaused
 women without contraception.

 -  Primary hyperparathyroidism group:secondary hyperparathyroidism, creatinine clearance
 <60 ml/min, liver insufficiency, psychiatric disorder able to modify the compliance to
 the study, tobacco intoxication, taking a treatment known to modify calcium-phosphorus
 status, severe known allergy, pregnant women.